Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – What’s Next?

Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down before the market opened on Monday . The stock had previously closed at $49.0192, but opened at $39.92. Zealand Pharma A/S shares last traded at $38.75, with a volume of 9,921 shares trading hands.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday. Cantor Fitzgerald restated a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. William Blair restated a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Finally, BNP Paribas Exane cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Three investment analysts have rated the stock with a Strong Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Trading Down 22.4%

The firm has a market cap of $2.76 billion, a P/E ratio of 2.86 and a beta of 0.86. The firm’s fifty day moving average is $48.10 and its two-hundred day moving average is $59.39. The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.50. The business had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $2.81 million. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. Analysts predict that Zealand Pharma A/S will post 2.37 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.